Eptinezumab in Participants With Episodic Cluster Headache
Completed · Phase 3 · NCT04688775
Conditions: Cluster Headache, Episodic
At a glance
- Research payments reported, 2025
- $7,968
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 231
About the trial
- Sponsor
- H. Lundbeck A/S
- Tested
- Eptinezumab (drug), Placebo (drug)
- Dates
- Started 2020-12-23; completion 2023-10-05
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
From ClinicalTrials.gov, last updated 2024-08-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
H. Lundbeck A S reported $7,968 in research payments for this study in 2025 (4 payments).
Products named: Vyepti
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Shane M. Root, M.D. Neurology · Scottsdale, AZ
- Deborah A. Burke, MD Neurology · Tampa, FL
- Brett R. Dees, MD Neurology · Oklahoma City, OK
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hightower Clinical LLC $6,318
- Sandhill Research LLC $1,600
- Dignity Health $50
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.